Early sales impress as Onyx's Kyprolis gets off to strong US start
This article was originally published in Scrip
Onyx Pharmaceuticals' sales of its recently approved multiple myeloma drug Kyprolis (carfilzomib) are off to an impressive start as the company reported $18.6 million in third quarter 2012 net sales on 2 November for the second-generation proteasome inhibitor, which was launched in the middle of the quarter.
You may also be interested in...
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.
Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.